Interv Akut Kardiol. 2022;21(3):174-177 | DOI: 10.36290/kar.2022.029

The EMPULSE Trial

Lenka Špinarová, Jindřich Špinar, Jiří Vítovec

I. interní kardioangiologická klinika Fakultní nemocnice u sv. Anny a LF MU, Brno

Since the publication of the 2021 Guidelines for the diagnosis and treatment of heart failure, gliflozins have been among the four cornerstones of the treatment for chronic heart failure (CHF). The efficacy of gliflozins has been clearly demonstrated in patients with reduced ejection fraction, regardless of the presence or absence of diabetes mellitus (the DAPA-HF and EMPEROR-Reduced trials). The SOLOIST-WHF was the first trial in patients with decompensated HF to have shown the benefit of sotagliflozin in diabetic patients. The EMPULSE trial evaluated the administration of empagliflozin in patients with acute HF following the stabilization of their clinical condition, regardless of diabetes mellitus or ejection fraction values. There was an improvement in the primary endpoint: death, rate of heart failure events (hospitalization for heart failure, urgent visit for heart failure, or unscheduled outpatient visit), time to first heart failure event, and change in the Kansas quality of life questionnaire between baseline and day 90. The results were consistent in the subgroups. The treatment was well tolerated, with the same adverse effects as in the placebo arm.

Keywords: pharmacotherapy, empagliflozin, decompensated heart failure.

Accepted: November 16, 2022; Published: November 21, 2022  Show citation